World renown George Clinical Scientific Leaders, researchers and project operations teams will be exhibiting at Booth 2626 and attending ASN Kidney Week in Washington, DC November 5 – 10, 2019.
Seven of our Scientific Leaders will be attending the ASN Kidney Week Conference:
• Vivekanand Jha
• David Wheeler
• Meg Jardine
• Martin Gallagher
• Hiddo Lambers Heerspink
• Muh Geot Wong
• Roberto Filho-Pecoits
Download this program to see a schedule of our Scientific Leaders’ presentations at ASN Kidney Week 2019.
Kidney Week provides attendees from across the globe opportunities to network, exchange knowledge and experiences within their fields, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field. Be sure to swing by our booth to learn more about the work we’ve done in renal clinical trials or to find out more information on our Scientific Leaders.
Get in touch today at firstname.lastname@example.org. Or contact us below to arrange a meeting with our scientific leaders or stop by Booth 2626 in the exhibit hall to learn more about our work in the Asia-Pacific and experience as a global CRO.
Hiddo Lambers Heerspink is affiliated with the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, the Netherlands. He received his PhD from the medical faculty of the University Medical Center Groningen in 2008. He then worked as a post-doctoral fellow at The George Institute in Sydney, Australia where he investigated the effects of blood pressure lowering regimens on renal and cardiovascular outcomes in patients with renal impairment. Based on this work, he was awarded a young investigator grant and, subsequently in 2015, a consolidator investigator grant from the Dutch organization of scientific research.
Since 2010, Professor Heerspink has held a position as a Clinical Pharmacologist at the University Medical Center Groningen. He is currently Professor Clinical Trials and Personalized Medicine. His main research interests include optimizing treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease. His clinical research interest is to identify determinants of individual treatment responses and ways to optimize drug response in individual patients. To achieve these goals, he is involved in various international clinical trials and uses biomarkers and imaging techniques to unravel pathways and determinants of therapy response.
Martin holds positions as Associate Professor, Faculty of Medicine, UNSW Sydney, Associate Professor of Medicine at Concord Hospital Clinical School (part of the Sydney Medical School), Director of the Renal and Metabolic Division in the George Institute and a clinical nephrologist in the Renal Dept. at Concord Repatriation and General Hospital. He works extensively in the ANZ Society of Nephrology in renal guidelines and clinical policy.
Martin’s research interests include large scale clinical trials to explore ways to improve the outcomes of patients with kidney disease (esp. in the setting of acute kidney injury), extending the follow up of such clinical trials to understand the long-term effects of treatments, measurement of health systems and the means of applying research evidence into practice.
Professor Vivekanand Jha is the Executive Director, The George Institute for Global Health, India, and James Martin Fellow at The George Institute for Global Health at the University of Oxford.
Prior to joining The George Institute, he was Professor of Nephrology and Head, Department of Translational Regenerative Medicine and Officer-In-Charge, Medical Education and Research Cell at the Postgraduate Institute of Medical Education and Research in Chandigarh, India. Vivek serves on the international advisory boards of several organizations, including membership of the WHO Expert Advisory Panel on Human Cell, Tissue and Organ Transplantation, and the executive committee of the International Society of Nephrology.
He is on the EMJ Editorial Board, counselor of the International Society of Nephrology, a member of the education committees for the International Transplantation Society and International Society of Peritoneal Dialysis. He is a physician with a specialization in the area of kidney diseases and he focuses on emerging public health threats globally and in India. He is particularly interested in using multi-disciplinary approaches and innovation to address the major challenge posed to humanity by non-communicable diseases.
A/Prof Meg Jardine is a clinician researcher developing a program of research exploring the cardiovascular and other complications of chronic kidney disease and diabetes.
Dr. Jardine has worked as a Nephrologist in both the public and private sectors, where she directly manages chronic kidney disease and diabetes and their consequences for patients.
She is currently Deputy Director of the Renal & Metabolic Division at the George Institute for Global Health; Associate Professor at the Faculty of Medicine, UNSW Sydney; and holds an NHMRC Career Development Fellowship. She has presented her work in late breaking and prize sessions of the World Congress of Nephrology and the Australasian Nephrology conference and has published in high impact journals. Dr. Jardine is collaborating on the development and delivery of other national and international trials investigating methods to mitigate the excess burden of cardiovascular disease and is Chair of the Australasian Kidney Trials Network Haemodialysis Working Group.
David is Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid lowering regimens, calcimimetics and sodium glucose cotransporter 2 inhibitors in patients chronic kidney disease. He has developed clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently Co-Chair. He is Past President of the UK Renal Association, past chair of the UK Renal Registry and currently National Institute for Health Research (NIHR) National Specialty Lead for Nephrology.
Walter E. Washington Convention Center
801 Mt Vernon Pl NW
Meet with George Clinical! Contact us to schedule a time now.